Merck's Keytruda reduced risk of disease recurrence or death in early lung cancer patients by 24%

Merck plans to submit the data on early stage lung cancer to the FDA as soon as possible.

from Health and Science https://ift.tt/H3QfdYE
https://ift.tt/4nJdDjx
https://ift.tt/rvJLgFf